Lilly's Zepbound (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks
Common Adherence and Tolerance Factors Often Mistaken for Non-Response GI side effectsnausea, constipation, delayed gastric emptyingcause some patients to underdose or discontinue rather than titrate properly
They answered all my questions and ensured I was comfortable with the ordering process
Do not take GLP-1 Medications if you are a Type I Diabetic on Insulin, family history of Medullary Thyroid Carcinoma (MTC), Multiple Endocrine Neoplasia 2 (MEN2), history of Pancreatitis or Gastroparesis (stomach paralysis), Pregnant, Breastfeeding, or a Type II Diabetic taking another GLP-1 Medication (Victoza, Trulicity, etc.), Chronic Kidney Disease
Anxiety-like behavior as an early endophenotype in the TgF344-AD rat model of Alzheimers disease